arGEN-X Launches Initial Public Offering on Euronext Brussels

June 20, 2014

Breda, the Netherlands / Ghent, Belgium – arGEN-X, a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced the launch of its Initial Public Offering on Euronext Brussels.